GOSS
Price
$0.91
Change
-$0.00 (-0.00%)
Updated
Sep 16 closing price
56 days until earnings call
SYRE
Price
$28.96
Change
-$0.00 (-0.00%)
Updated
Sep 16 closing price
51 days until earnings call
Ad is loading...

GOSS vs SYRE

Header iconGOSS vs SYRE Comparison
Open Charts GOSS vs SYREBanner chart's image
Gossamer Bio
Price$0.91
Change-$0.00 (-0.00%)
Volume$630.8K
CapitalizationN/A
Spyre Therapeutics
Price$28.96
Change-$0.00 (-0.00%)
Volume$701.23K
CapitalizationN/A
View a ticker or compare two or three
GOSS vs SYRE Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
GOSS vs. SYRE commentary
Sep 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and SYRE is a Hold.

COMPARISON
Comparison
Sep 18, 2024
Stock price -- (GOSS: $0.91 vs. SYRE: $28.96)
Brand notoriety: GOSS and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 61% vs. SYRE: 158%
Market capitalization -- GOSS: $205.87M vs. SYRE: $1.47B
GOSS [@Biotechnology] is valued at $205.87M. SYRE’s [@Biotechnology] market capitalization is $1.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $606.74B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both GOSS and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • GOSS’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than GOSS.

Price Growth

GOSS (@Biotechnology) experienced а -2.15% price change this week, while SYRE (@Biotechnology) price change was -0.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.17%. For the same industry, the average monthly price growth was +6.90%, and the average quarterly price growth was +0.15%.

Reported Earning Dates

GOSS is expected to report earnings on Nov 12, 2024.

SYRE is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (+4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.48B) has a higher market cap than GOSS($206M). SYRE YTD gains are higher at: 34.572 vs. GOSS (-0.274). GOSS has higher annual earnings (EBITDA): -59.72M vs. SYRE (-172.92M). SYRE has more cash in the bank: 426M vs. GOSS (354M). SYRE has less debt than GOSS: SYRE (0) vs GOSS (199M). GOSS has higher revenues than SYRE: GOSS (95.8M) vs SYRE (0).
GOSSSYREGOSS / SYRE
Capitalization206M1.48B14%
EBITDA-59.72M-172.92M35%
Gain YTD-0.27434.572-1%
P/E RatioN/A2.66-
Revenue95.8M0-
Total Cash354M426M83%
Total Debt199M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
43
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GOSSSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 23 days ago
83%
Bullish Trend 13 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 27 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NUIAX31.560.25
+0.80%
Nuveen International Dividend Growth A
ETLIX14.790.09
+0.61%
Eventide Large Cap Focus I
OSVCX18.640.11
+0.59%
JPMorgan Small Cap Value C
MASNX10.930.01
+0.09%
iMGP Alt Strats Inv
JHDCX17.91N/A
N/A
JPMorgan Hedged Equity 2 C

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ACIU. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ACIU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-1.36%
ACIU - SYRE
51%
Loosely correlated
+2.83%
SNPX - SYRE
47%
Loosely correlated
-2.85%
PMN - SYRE
44%
Loosely correlated
+12.20%
GOSS - SYRE
41%
Loosely correlated
-1.24%
MLTX - SYRE
41%
Loosely correlated
-2.27%
More